Skip to content
value.today

Theriva Biologics, Inc.

TOVX
$10 Mmarket cap on Oct 13, 2026+26.3% since Jan 2024
Compare
World rank
#25,846
Revenue
—
For year ending December-2025
Net income
$-24 M
SEC filing
Employees
15
As of March 12, 2026
SEC filing

Theriva Biologics, Inc. in brief

Theriva Biologics, Inc. is a listed company in the Biotechnology industry, based in Rockville, Maryland, USA. Its market value was $10 M on 13 October 2026, which makes it the 25,846th largest listed company in the world and the 4,298th largest in the USA on this site. It employs about 15 people. Its shares trade under the symbol TOVX (NYSE).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Theriva Biologics, Inc.

We are a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. As a result of the Company’s acquisition of Theriva Biologics, S.L., in March 2022, as described in more detail below, we transitioned our strategic focus to oncology through the development of VCN’s new oncolytic adenovirus platform designed for intravenous and intravitreal delivery to trigger tumor cell death, to improve access of co-administered cancer therapies to the tumor, and to promote a robust and sustained anti-tumor response by the patient’s immune system. Our lead product candidate, VCN - 01 (zabilugene almadenorepvec), is a clinical stage oncolytic human adenovirus that is modified for tumor - selective replication and to express an enzyme, PH20 hyaluronidase. VCN - 01 has been evaluated in a Phase 2b clinical study for the treatment of pancreatic cancer, and a Phase 1 clinical study for the treatment of retinoblastoma, as well as various other Phase 1 clinical studies for the treatment of other solid tumors including head and neck squamous cell carcinoma.

From the company's annual report filed with the US SEC: read the report

Theriva Biologics, Inc. timeline

6 events, 1996–2022
  1. 1996
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 1997
  4. ✎
    Renamed Sheffield Pharmaceuticals Inc
    Formerly Sheffield Medical Technologies Inc.
  5. 2006
  6. ✎
    Renamed Pipex Pharmaceuticals, Inc.
    Formerly Sheffield Pharmaceuticals Inc.
  7. 2008
  8. ✎
    Renamed Adeona Pharmaceuticals, Inc.
    Formerly Pipex Pharmaceuticals, Inc..
  9. 2012
  10. ✎
    Renamed Synthetic Biologics, Inc.
    Formerly Adeona Pharmaceuticals, Inc..
  11. 2022
  12. ✎
    Renamed Theriva Biologics, Inc.
    Formerly Synthetic Biologics, Inc..

Events of Theriva Biologics, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$3 M$5 M$8 M$11 M2023202420252026

World rank over time

▲ up 6,327 places since 2022
2022-12-25: #32187#32,18720222023-07-30: #31611#31,61120232024-01-05: #31699#31,69920242026-03-08: #12893#12,89320262026-08-01: #22947#22,94720262026-10-13: #25860#25,8602026

Rank in USA: #5,674 (Dec 2022) · #5,421 (Jul 2023) · #4,557 (Jan 2024) · #2,400 (Mar 2026) · #4,048 (Aug 2026) · #4,247 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
0.7×
Free cash flow yield
-165.4%
Net margin
—
Operating margin
—
Return on equity
-154.4%
Liabilities / assets
59.8%
Net debt
$-11M
R&D / revenue
60.5%
Profit per employee
$-1.6 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue —, net income $-13M—FY18Fiscal year ending Dec 2019: revenue —, net income $-15M—FY19Fiscal year ending Dec 2020: revenue —, net income $-10M—FY20Fiscal year ending Dec 2021: revenue —, net income $-14M—FY21Fiscal year ending Dec 2022: revenue —, net income $-20M—FY22Fiscal year ending Dec 2023: revenue —, net income $-18M—FY23Fiscal year ending Dec 2024: revenue —, net income $-26M—FY24Fiscal year ending Dec 2025: revenue —, net income $-24M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-24M$-24M—
Dec 2024——$-26M$-26M—
Dec 2023——$-21M$-18M—
Dec 2022——$-22M$-20M—
Dec 2021——$-14M$-14M—
Dec 2020——$-10M$-10M—
Dec 2019——$-16M$-15M—
Dec 2018——$-18M$-13M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-17M$0M$-17M$-2.08—
Dec 2024$-17M$0M$-17M$-19.03—
Dec 2023$-19M$0M$-19M$-28.48—
Dec 2022$-19M$0M$-19M$-1.31—
Dec 2021$-13M$0M$-13M$-1.90—
Dec 2020$-12M$0M$-12M$-0.66—
Dec 2019$-14M$0M$-14M$-0.98—
Dec 2018$-17M$0M$-17M$-4.06—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-4M—Dec ’24Three months to Mar 2025: revenue —, net income $-4M—Mar ’25Three months to Jun 2025: revenue —, net income $-13M—Jun ’25Three months to Sep 2025: revenue —, net income $-4M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-2M—Dec ’25Three months to Mar 2026: revenue $0M, net income $-2M$0MMar ’26Three months to Jun 2026: revenue —, net income $-3M—Jun ’26Three months to Sep 2026: revenue —, net income $-1M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-1M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Theriva Biologics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-24 M
Net income
$-24 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$38 M
Total liabilities
$23 M
Total equity
$15 M

As of December-2025

Top 26 institutional investors in Theriva Biologics, Inc.#

As of Sep 30, 2026
26 institutions held 1.8 M shares (about 3.9% of the shares outstanding) on Sep 30, 2026. The ten largest hold 3.7%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Theriva Biologics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Vanguard Capital Management LLC486,1790 (0.00%)1.06%$0 MNov 13, 2026
2Geode Capital Management, LLC299,138+5,117 (+1.74%)0.65%$0 MNov 6, 2026
3Vanguard Fiduciary Trust Co241,7800 (0.00%)0.53%$0 MNov 13, 2026
4Jane Street Group, LLC161,106-170,816 (-51.46%)0.35%$0 MNov 12, 2026
5Ikarian Capital, LLC112,0760 (0.00%)0.24%$0 MNov 16, 2026
6Renaissance Technologies LLC109,500+45,790 (+71.87%)0.24%$0 MNov 12, 2026
7XTX Topco Ltd102,846+48,978 (+90.92%)0.22%$0 MNov 16, 2026
8Northern Trust Corp82,7000 (0.00%)0.18%$0 MNov 16, 2026
9Two Sigma Securities, LLC55,904+36,156 (+183.09%)0.12%$0 MNov 16, 2026
10StoneX Group Inc.32,106New0.07%$0 MNov 3, 2026
11Boothbay Fund Management, LLC27,6460 (0.00%)0.06%$0 MNov 16, 2026
12Morgan Stanley20,2990 (0.00%)0.04%$0 MNov 13, 2026
13Ground Swell Capital, LLC18,410-16,882 (-47.84%)0.04%$0 MNov 9, 2026
14Two Sigma Investments, LP15,437-19 (-0.12%)0.03%$0 MNov 16, 2026
15Schwarz Dygos Wheeler Investment Advisors LLC15,0000 (0.00%)0.03%$0 MNov 10, 2026
16UBS Group AG13,983-47,070 (-77.10%)0.03%$0 MNov 10, 2026
17BlackRock, Inc.7,5040 (0.00%)0.02%$0 MNov 13, 2026
18SBI Securities Co., Ltd.1,083+725 (+202.51%)0.00%$0 MOct 22, 2026
19Osaic Holdings, Inc.440-1 (-0.23%)0.00%$0 MNov 12, 2026
20Strategic Financial Concepts, LLC163New0.00%$0 MNov 16, 2026
21IFP Advisors, Inc110 (0.00%)0.00%$0 MOct 16, 2026
22Tower Research Capital LLC (TRC)5New0.00%$0 MNov 16, 2026
23NFSG Corp50 (0.00%)0.00%$0 MOct 15, 2026
24Barclays PLC30 (0.00%)0.00%$0 MNov 6, 2026
25Wells Fargo & Company/mn2New0.00%$0 MNov 16, 2026
Show all 26: investors 26 to 26
Institutional investors 26 to 26 in Theriva Biologics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Danske Bank A/s10 (0.00%)0.00%$0 MNov 9, 2026

Mutual funds holding Theriva Biologics, Inc.#

4 funds hold shares worth $0 M (about 1.7% of the company). Since their previous reports 2 added shares and 0 sold, buying $0 M net.
Mutual funds holding Theriva Biologics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.486,179$0 M1.1%<0.01%+153%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC284,723$0 M0.62%<0.01%+48%May 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC26,070$0 M0.06%<0.01%no changeMay 31, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC31$0 M<0.01%<0.01%no changeJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 4 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Theriva Biologics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
10
since
Theriva Biologics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Steven A. ShallcrossCEO and CFO, DirectorBuy+14,000$0.690$10 K250,000Form 4
filed Steven A. ShallcrossCEO and CFO, DirectorBuy+26,000$0.630$16 K236,000Form 4
filed Steven A. ShallcrossCEO and CFO, DirectorBuy+25,000$1.040$26 K210,000Form 4
filed Steven A. ShallcrossCEO and CFO, DirectorBuy+25,000$0.940$24 K185,000Form 4
filed Steven A. ShallcrossCEO and CFO, DirectorBuy+25,000$0.870$22 K160,000Form 4
filed Steven A. ShallcrossCEO and CFO, DirectorBuy+25,000$0.750$19 K135,000Form 4
filed Steven A. ShallcrossCEO and CFO, DirectorBuy+100,000$0.440$44 K110,000Form 4
filed Steven A. ShallcrossCEO and CFO, DirectorBuy+50,000$0.490$25 K100,000Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Theriva Biologics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
1.4 M
4.0% of shares · 2.74 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-25 reverse split ; 10-for-1 split

Bankruptcy filing: (8-K)

Fails to deliver

  • : 93,707 shares at $0.22
  • : 26,663 shares at $0.23
  • : 7,920 shares at $0.23
  • : 3,982 shares at $0.23
  • : 3,050 shares at $0.23

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Theriva Biologics, Inc. scorecard#

Passes 4 of the 14 checks that could be worked out: strongest in financial health (3 of 5), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 13, 2026.

  • Valuation1 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median0.7×Price to book 0.7× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-165.4%Free cash flow is -165.4% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-2.08 vs -19.03Diluted EPS -2.08 in fiscal 2025 against -19.03 the year before (report's currency).
    • ✗Net income higher than five years earlier-$24 M-$24 M in fiscal 2025 against -$10 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$24 MNet income -$24 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-137.8%-137.8% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health3 of 5
    • ✓Short-term assets cover short-term liabilities1.8×Current ratio 1.75 at the end of fiscal 2025.
    • ✓Debt below equity0.1×Debt to equity 0.11 at the end of fiscal 2025.
    • ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $11 M at the end of fiscal 2025.
    • ✗Operating income covers interest five times-400.8×Operating income -400.8 times interest in fiscal 2025.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Theriva Biologics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Theriva Biologics, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Research and development8.61214127.85.111121929
General and administrative157.47.19.96.55.04.65.77.510
Operating expenses24262122141016182639
Operating income−24−26−21−22−14−10−16−18−26−39
Interest and finance income0.30.71.40.50.00.00.30.10.00.0
Interest expense and finance costs0.10.0————————
Other non-operating income (expense)0.30.71.40.50.00.00.34.21111
Income before tax−24−26−20−21−14—————
Income tax—0−1.6−1.4000000
Net income including minority interests−24−26−18−20−14−10−15−13−15−28
Minority interests' share of net income———0−0.0−0.1−0.1−0.1−0.3−0.5
Net income attributable to shareholders——−18−20−14−10−15−13−15−27
Earnings per share, basic-2.08-19.03-28.48r-1.31-1.90r-0.66-0.98-4.06-6.23r-0.29
Earnings per share, diluted-2.08-19.03-28.48r-1.31-1.90r-0.66-0.98-4.06-6.23r-0.29
Shares, weighted average (basic)121.30.6r1512r19————
Shares, weighted average (diluted)121.30.6r1512r19166.23.6r94
Balance sheet
Cash and cash equivalents13122342676.215291719
Other current assets1.11.42.43.71.51.71.40.60.80.2
Current assets17162746697.916301822
Property, plant and equipment0.20.30.40.30.10.20.40.60.90.9
Right-of-use (leased) assets0.81.31.81.21.40.30.40——
Goodwill—05.75.50—————
Other intangible assets20172019——————
Total assets38355572708.417301922
Accounts payable1.00.90.80.90.50.92.31.02.02.0
Current liabilities107.66.77.13.63.05.33.49.820
Lease liabilities (non-current)0.40.91.41.21.40.20.50——
Total liabilities231616175.03.25.73.71020
Retained earnings−359−335−309−291−271−248−236−219−194−172
Shareholders' equity————65−4.81.817−1.53.8
Minority interests—————−2.8−2.9−2.9−1.9−1.6
Total equity1519375265−7.5−1.114r−3.42.3r
Total liabilities and equity38355572708.417301922
Shares outstanding362.80.7r15r13r2917153.7r117
Cash-flow statement
Depreciation and amortization0.10.10.10.10.10.20.20.30.20.2
Share-based compensation0.70.70.60.50.40.40.32.13.44.0
Cash from operating activities−17−17−19−19−13−12−14−17−20−28
Capital expenditure−0.0−0.0−0.2−0.1−0.0−0.00−0.0−0.2−0.6
Cash from investing activities−0.0−0.0−0.2−4.4−0.0−0.00−0.0−0.2−0.6
Debt issued1.5—————————
Debt repaid—−0.1−0.1−1.40—————
Shares issued———0663.4—12025
Cash from financing activities185.50.6−1.9743.40291827
Exchange-rate effect on cash−0.1−0.1−0.0−0.00—————
Change in cash1.4−12−19−2561—————
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at Theriva Biologics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Restructuring 1 · Acquisition or sale completed 1 · Directors and officers 2 · Material agreement 3 · Unregistered share sale 1 · Shareholder vote 2 · Results announced 5

Theriva Biologics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Acquisition or sale completedMaterial agreement8-K
Results announced8-K
Directors and officersShareholder vote8-K
Results announced8-K
Results announced8-K
Material agreement8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Restructuring8-K
Directors and officersShareholder vote8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

2 private funding rounds before listing

Private share sales · funding history

Private share sales of Theriva Biologics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2025$13 MPrivate placement after listing$10 to $50 million10optionsSEC
Jul 2022$3 MPrivate placement after listing$2 to $10 million1equitySEC
Mar 2022$1 MPrivate placement after listingUnder $2 million4equitySEC
Sep 2017$12 MPrivate placement after listing$10 to $50 million1equitySEC
Oct 2012$11 MNo. 2$10 to $50 million22equitySEC
Oct 2012$8 MNo. 1$2 to $10 million1equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Layoffs at Theriva Biologics, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
8
2018–2025
Latest
—
2025-09-28
Theriva Biologics, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2025············—
2018··········8·8
Theriva Biologics, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
Not statedRestructuring planSEC 8-KCompany-wide planFiling
8 people (33% of workforce)Restructuring planSEC 8-K“The reduction included 8 employees, which represented approximately 33% of its workforce as of November 29, 2018, the date affected employees were notified.”Filing

Source: State WARN notices and SEC 8-K item 2.05

How Theriva Biologics, Inc. compares in Biotechnology

  • Market cap$10 M · higher than 10% of 726
  • Price / book0.7× · lower than 87% of 534
  • FCF yield-165.4% · higher than 3% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Theriva Biologics, Inc.🇺🇸$10 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 13, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of March 12, 2026
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Theriva Biologics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Theriva Biologics, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Theriva Biologics, Inc.? Suggest a correction